Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT.

Literature DB >> 32086243

Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using ¹⁸F-FDG PET/CT.

Romain-David Seban, Lawrence H Schwartz, Gerald Bonardel, Laurent Dercle¹.

Abstract

Entities: Disease Species

Year: 2020 PMID： 32086243 DOI： 10.2967/jnumed.120.242768

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057

Keyword Cloud
Cited

× No keyword cloud information.

3 in total

Review 1. Interpretation of 2-[¹⁸F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.

Authors: Guillaume Manson; Amaeshi Chukwunonye Lemchukwu; Fatima-Zohra Mokrane; Egesta Lopci; Nicolas Aide; Laetitia Vercellino; Roch Houot; Laurent Dercle
Journal: Eur Radiol Date: 2022-03-28 Impact factor: 7.034

2. Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline ¹⁸F-FDG PET/CT in Metastatic Melanoma.

Authors: Romain-David Seban; Laurence Champion; Izza Muneer; Shwe Synn; Lawrence H Schwartz; Laurent Dercle
Journal: J Nucl Med Date: 2021-05-28 Impact factor: 11.082

3. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.

Authors: E Lopci; R J Hicks; A Dimitrakopoulou-Strauss; L Dercle; A Iravani; R D Seban; C Sachpekidis; O Humbert; O Gheysens; A W J M Glaudemans; W Weber; R L Wahl; A M Scott; N Pandit-Taskar; N Aide
Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-04 Impact factor: 10.057

3 in total

Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT.

Review 1. Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.

2. Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline 18F-FDG PET/CT in Metastatic Melanoma.

3. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.

Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using ¹⁸F-FDG PET/CT.

Review 1. Interpretation of 2-[¹⁸F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.

2. Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline ¹⁸F-FDG PET/CT in Metastatic Melanoma.

3. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.